Molecular Pharmacology Shared Resource

分子药理学共享资源（MPSR） 项目总结/摘要 分子药理学共享资源（MPSR）在加州大学戴维斯分校综合癌症中心 （UCDCCC）提供集中服务，开展临床药代动力学（PK）/药效学（PD）研究 和新疗法的临床前建模。了解单个药物的PK/PD特性至关重要 用于临床前和临床药物开发，以及癌症精准医疗的临床实践。许多 在UCDCCC进行的临床研究，包括药物启动的临床试验（IIT）或国家癌症研究中心（National Cancer 研究所（NCI）资助的实验治疗药物临床试验网络（ETCTN）试验，以及国家 临床试验网络（NCTN）试验，其中UCDCCC是主要学术参与研究中心，涉及 PK/PD特性和靶向药理学作用的评估。同时，定义药物代谢 (DM)在转化新的治疗药物之前，适当的临床前模型中的PK/PD特征至关重要 药物进入临床研究。MPSR为高质量的收集提供全面的服务， 处理和分析试验患者的临床标本，以评估临床PK/PD和临床前 评估新的治疗方法和方案，包括DM/PK/PD、靶向机制、生物标志物， 药物相互作用（DDI）和联合效应。此外，MPSR通过以下方式为IIT提供支持： 帮助开发方案和检测方法。最近获得了最先进的活细胞代谢 分析平台，海马XFe分析仪，将进一步加强基础和转化研究， 癌症代谢的领域在UCDCCC。公共部门社会责任司司长负责监督和管理， Yu Aiming博士是DM/PK领域的世界领先者，研究DM/PK/PD的分子机制， 抗癌药理学，和技术经理，安东尼马丁内斯，BS，助理主任的 临床研究办公室（OCR），拥有超过7年的临床试验经验和20年的癌症经验 research. MPSR的具体目标是：1）临床试验标本管理，其中MPSR 监督入组临床试验的患者的生物标本采集、处理和储存 在UCDCCC; 2）方案开发和临床PK/PD研究，其中MPSR支持研究设计， 和方案开发，开发新的内部分析，并进行药物的靶向分析， 代谢物和生物标志物，进行PK/PD数据分析和解释;和3）临床前建模， MPSR评估新的药物和治疗方法，用于精确医学，这些药物和治疗方法可以转化为 诊所

MOLECULAR PHARMACOLOGY SHARED RESOURCE (MPSR) PROJECT SUMMARY/ABSTRACT The Molecular Pharmacology Shared Resource (MPSR) at the UC Davis Comprehensive Cancer Center (UCDCCC) has centralized services to conduct clinical pharmacokinetic (PK)/pharmacodynamic (PD) studies and preclinical modeling of new therapeutics. Understanding PK/PD properties of individual drugs is essential for preclinical and clinical drug development, as well as clinical practice of precision medicine in cancer. Many clinical studies conducted at the UCDCCC, including investigator-initiated clinical trials (IIT) or National Cancer Institute (NCI)-funded Experimental Therapeutics Clinical Trials Network (ETCTN) trails, and the National Clinical Trials Network (NCTN) trials for which UCDCCC is a Lead Academic Participating Site, involve the assessment of PK/PD properties and on-target pharmacological actions. Meanwhile, defining drug metabolism (DM) and PK/PD characteristics in appropriate preclinical models is vital before translating new therapeutic drugs into clinical investigations. The MPSR provides comprehensive services for high-quality collection, processing and analysis of clinical specimens from trial patients to assess clinical PK/PD, and preclinical assessment of novel therapeutics and regimens, including DM/PK/PD, on-target mechanisms, biomarkers, drug-drug interactions (DDI) and combination effects. In addition, the MPSR provides support for IITs by helping with protocol and assay development. Very recent acquisition of a state-of-the-art, live-cell metabolic assay platform, the Seahorse XFe Analyzer, will further strengthen basic and translational research in the areas of cancer metabolism at UCDCCC. Oversight and management of the MPSR is provided by the Director, Aiming Yu, PhD, a world leader in the fields of DM/PK, studying molecular mechanisms of DM/PK/PD and anticancer pharmacology, and the Technical Manager, Anthony Martinez, BS, the Assistant Director of the Office of Clinical Research (OCR), with over 7 years' experience in clinical trials and 20 years' in cancer research. The Specific Aims for the MPSR are: 1) Clinical Trial Specimen Management, in which the MPSR oversees biospecimens collection, processing and storage for patients enrolled on clinical trials conducted at UCDCCC; 2) Protocol Development and Clinical PK/PD studies, in which the MPSR supports study design, and protocol development, develops new in-house assays and conducts targeted analyses of drugs, metabolites and biomarkers, performs PK/PD data analysis and interpretation; and 3) Preclinical Modeling in which the MPSR evaluates new agents and treatments for precision medicine that are translatable to the clinic.